What RA Capital Management, L.P. reported holding on Form 13F for the quarter ended Jun 30, 2026.
CIK 1346824 · Filed Aug 14, 2026
Values are as the managers reported them, in dollars.Open the Form 13F on SEC EDGAR
| 28.9M |
| New |
| $791.9M |
| 6.9% |
RYTMRhythm Pharmaceuticals, Inc. | 6.7M | New | $740.2M | 6.4% |
PCVXVaxcyte, Inc. | 11.5M | New | $667M | 5.8% |
SIONSionna Therapeutics, Inc. | 9.9M | New | $435.7M | 3.8% |
TYRATyra Biosciences, Inc. | 12.2M | New | $389.6M | 3.4% |
EWTXEdgewise Therapeutics, Inc. | 8.4M | New | $341M | 3% |
NAMSNewAmsterdam Pharma Co N.V. | 9.6M | New | $323.7M | 2.8% |
COAGHemab Therapeutics Holdings, Inc. | 7.8M | New | $286.8M | 2.5% |
SEPNSepterna, Inc. | 7M | New | $234.3M | 2% |
BCAXBicara Therapeutics Inc. | 7.3M | New | $215.4M | 1.9% |
MLYSMineralys Therapeutics, Inc. | 7.7M | New | $207.6M | 1.8% |
GHRSGH Research PLC | 7.6M | New | $205.3M | 1.8% |
IRONDisc Medicine, Inc. | 2.5M | New | $179.2M | 1.6% |
SGPSpyGlass Pharma, Inc. | 8M | New | $178.6M | 1.6% |
ARTVArtiva Biotherapeutics, Inc. | 18M | New | $174.2M | 1.5% |
JANXJanux Therapeutics, Inc. | 11.2M | New | $171.9M | 1.5% |
TSHATaysha Gene Therapies, Inc. | 23.6M | New | $160.4M | 1.4% |
BCRXBiocryst Pharmaceuticals Inc | 15.8M | New | $158.3M | 1.4% |
WVEWave Life Sciences, Inc. | 27M | New | $156.7M | 1.4% |
NUVLNuvalent, Inc. | 1.2M | New | $153.9M | 1.3% |
ABVXAbivax S.A. | 1.1M | New | $150.9M | 1.3% |
ORKAOruka Therapeutics, Inc. | 1.6M | New | $148M | 1.3% |
CLYMClimb Bio, Inc. | 11.3M | New | $147.4M | 1.3% |
SLDBSolid Biosciences Inc. | 12M | New | $120.2M | 1% |
ZLABZai Lab Ltd | 5.7M | New | $109.1M | 0.9% |
SPRYARS Pharmaceuticals, Inc. | 10.9M | New | $87M | 0.8% |
XNCRXencor Inc | 5.3M | New | $84.9M | 0.7% |
JBIOJade Biosciences, Inc. | 3.7M | New | $81.6M | 0.7% |
NTLAIntellia Therapeutics, Inc. | 4.5M | New | $76.6M | 0.7% |
LBRXLB Pharmaceuticals Inc | 2.2M | New | $71.7M | 0.6% |
DFTXDefinium Therapeutics, Inc. | 1.5M | New | $70.6M | 0.6% |
ACRSAclaris Therapeutics, Inc. | 12.7M | New | $67.3M | 0.6% |
FDMT4D Molecular Therapeutics, Inc. | 5M | New | $67.2M | 0.6% |
SANASana Biotechnology, Inc. | 18.8M | New | $65.4M | 0.6% |
DMRADamora Therapeutics, Inc. | 2.4M | New | $62.4M | 0.5% |
MNPRMonopar Therapeutics | 667.2K | New | $61.8M | 0.5% |
ABOSAcumen Pharmaceuticals, Inc. | 21M | New | $56.1M | 0.5% |
GERNGeron Corp | 42.8M | New | $54.8M | 0.5% |
RZLTRezolute, Inc. | 9.4M | New | $49.1M | 0.4% |
EVMNEvommune, Inc. | 3.5M | New | $46.4M | 0.4% |
VORVor Biopharma Inc. | 2.4M | New | $44.2M | 0.4% |
IPSCCentury Therapeutics, Inc. | 17.8M | New | $43.5M | 0.4% |
AKTSAktis Oncology, Inc. | 1.3M | New | $42.4M | 0.4% |
BIOABioAge Labs, Inc. | 1.7M | New | $41M | 0.4% |
CCCCC4 Therapeutics, Inc. | 8M | New | $37.4M | 0.3% |
MIRMMirum Pharmaceuticals, Inc. | 318.6K | New | $37.3M | 0.3% |
CAPRCapricor Therapeutics, Inc. | 1.5M | New | $36.3M | 0.3% |
PEPGPepGen Inc. | 20.1M | New | $36.1M | 0.3% |
PRLDPrelude Therapeutics Inc | 6.5M | New | $34.5M | 0.3% |
NKTXNkarta, Inc. | 10.8M | New | $30.6M | 0.3% |
QTTBQ32 Bio Inc. | 2.3M | New | $29.7M | 0.3% |
AVRAnteris Technologies Global Corp. | 3M | New | $29.6M | 0.3% |
EDITEditas Medicine, Inc. | 8.9M | New | $28.8M | 0.3% |
OVIDOvid Therapeutics Inc. | 10.5M | New | $28.2M | 0.2% |
ASMBAssembly Biosciences, Inc. | 1M | New | $28M | 0.2% |
ALXOALX Oncology Holdings Inc | 13M | New | $26.9M | 0.2% |
BNTCBenitec Biopharma Inc. | 1.9M | New | $24.8M | 0.2% |
LENZLENZ Therapeutics, Inc. | 4.2M | New | $23.7M | 0.2% |
LXEOLexeo Therapeutics, Inc. | 5M | New | $23.3M | 0.2% |
ACRVAcrivon Therapeutics, Inc. | 12.2M | New | $21.8M | 0.2% |
ALTAltimmune, Inc. | 6.5M | New | $19.8M | 0.2% |
KPTIKaryopharm Therapeutics Inc. | 1.9M | New | $18.7M | 0.2% |
DRUGBright Minds Biosciences Inc. | 265K | New | $18.6M | 0.2% |
AVTXAvalo Therapeutics, Inc. | 1M | New | $18.5M | 0.2% |
OKUROnKure Therapeutics, Inc. | 4M | New | $18.2M | 0.2% |
FTHFaeth Therapeutics, Inc. | 722K | New | $18.1M | 0.2% |
AURAAura Biosciences, Inc. | 2.5M | New | $17.8M | 0.2% |
SABSSAB Biotherapeutics, Inc. | 4.4M | New | $17.2M | 0.1% |
SPTXSeaport Therapeutics, Inc. | 700K | New | $15.2M | 0.1% |
PALIPalisade Bio, Inc. | 7.1M | New | $14.9M | 0.1% |
HLXCHelix Acquisition Corp. III | 1.3M | New | $13.3M | 0.1% |
WAYWaystar Holding Corp. | 529.4K | New | $10.9M | 0.1% |
EQEquillium, Inc. | 3.1M | New | $9.9M | 0.1% |
MGNXMacrogenics Inc | 1.9M | New | $8.6M | 0.1% |
PCSCFreenome, Inc. | 750K | New | $8.2M | 0.1% |
ACETAdicet Bio, Inc. | 932.6K | New | $8.1M | 0.1% |
NAMSWNewAmsterdam Pharma Co N.V. | 333.3K | New | $7.1M | 0.1% |
CRVSCorvus Pharmaceuticals, Inc. | 450K | New | $6.7M | 0.1% |
RANIRani Therapeutics Holdings, Inc. | 8.5M | New | $6.5M | 0.1% |
JATTJATT II Acquisition Corp. | 500K | New | $5.7M | 0.1% |
AMANAmanat Acquisition Corp. | 375K | New | $3.8M | 0.1% |
HOWLWerewolf Therapeutics, Inc. | 2.4M | New | $859.3K | 0.1% |
PTNPalatin Technologies Inc | 62.1K | New | $670.3K | 0.1% |
